Physician profile
Douglas Scott Jacoby
NPI 1477580371
$28,547.59
in general payments reported to CMS, 2019-2025
16 companies · $3,351 in 2025
The $3,351 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,266 · 2020: $5,907 · 2021: $5,823 · 2022: $2,148 · 2023: $4,811 · 2024: $242 · 2025: $3,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,750 · Food and Beverage: $654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,750.00 |
| Food and Beverage | $654.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $15,877.69 | 2019-2024 | Wainua |
| Novartis Pharmaceuticals Corporation | $5,402.29 | 2021-2025 | |
| Novo Nordisk INC | $4,712.61 | 2023-2024 | Ozempic, Rybelsus |
| Regeneron Healthcare Solutions, INC. | $2,095.50 | 2019-2021 | |
| Amgen INC. | $145.87 | 2023-2024 | Repatha |
| Heartflow, INC. | $102.54 | 2025 | |
| Abiomed | $33.80 | 2025 | |
| Acarix USA INC. | $27.22 | 2024 | Cadscor System |
| Alexion Pharmaceuticals, INC. | $25.86 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $25.26 | 2024 | Arcalyst |
| Abbott Laboratories | $22.08 | 2024 | Cardiomems |
| Siemens Medical Solutions USA, INC. | $19.90 | 2024 | Acuson Origin Diagnostic Ultrasound System |
| E.R. Squibb & Sons, L.L.C. | $18.66 | 2023 | Camzyos |
| Janssen Pharmaceuticals, INC | $18.02 | 2024 | Xarelto |
| Amarin Pharma, INC. | $16.14 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $4.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Jacoby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.